That said, because prolonged targeting of GM-CSF based therapies to the tumor microenvironment will eventually lead to the development of tolerogenic myeloid cells, dosage of GM-CSF to be administered must be carefully determined. The gene discussed is CSF2; the disease is neoplasm.